Nicox’s Partner Secures Approval of VYZULTA in Mexico

January 13, 2020

Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Mexico.

The approval in Mexico follows approvals of VYZULTA in the U.S. and Canada. VYZULTA is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Gavin Spencer, Chief Business Officer of Nicox, said: “VYZULTA is now approved in three major markets. This approval will contribute to Nicox revenue stream and it validates that Nicox is continuing to maximize the value from our partnered assets to complement our own development activities, further reinforced by our recent ZERVIATE license in South Korea and the forthcoming commercial launch of ZERVIATE in the U.S. by our partner Eyevance.”

Nicox receives increasing tiered net royalties of 6% to 12% on global sales of VYZULTA as well as up to $150 million in potential future milestones.

Bausch + Lomb is a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC).

← Back to blog page